Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and receptors in type 1, type 2 and type 17 inflammation in cross-sectional asthma study

Michelle Marks, Chad Steele, Wendy C. Moore, Deborah A. Meyers, Brian Rector, Elizabeth Ampleford, Eugene R. Bleecker, Annette T. Hastie

Research output: Contribution to journalArticlepeer-review

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) reportedly promotes, or conversely, resolves inflammation in asthma. In this study of TRAIL and cell receptors in sputum, bronchoalveolar lavage and biopsy from subjects in the Severe Asthma Research Program at Wake Forest, the high TRAIL group had significant increases in all leucocytes, and was associated with increased type 1, type 2 and type 17 cytokines, but not type 9 interleukin 9. Two variants at loci in the TRAIL gene were associated with higher sputum levels of TRAIL. Increased TRAIL decoy receptor R3/DcR1 was observed on sputum leucocytes compared with death receptor R1/DR4, suggesting reduced apoptosis and prolonged cellular inflammation.

Original languageEnglish (US)
Pages (from-to)808-811
Number of pages4
JournalThorax
Volume75
Issue number9
DOIs
StatePublished - Sep 1 2020
Externally publishedYes

Keywords

  • asthma mechanisms
  • cytokine biology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and receptors in type 1, type 2 and type 17 inflammation in cross-sectional asthma study'. Together they form a unique fingerprint.

Cite this